Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

KEYNOTE-A18 Data Support Pembrolizumab Plus CCRT as New SOC in High-Risk Cervical Cancer

June 2nd 2025, 7:01pm

ASCO Annual Meeting

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

Perioperative Nivolumab Sustains EFS Advantage in Resectable NSCLC, With Enriched Benefit in ctDNA–, pCR Responders

June 2nd 2025, 6:52pm

ASCO Annual Meeting

Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.

Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer

June 2nd 2025, 6:19pm

ASCO Annual Meeting

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.

Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC

June 2nd 2025, 4:39pm

ASCO Annual Meeting

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC

June 2nd 2025, 4:02pm

ASCO Annual Meeting

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer

June 2nd 2025, 4:00pm

ASCO Annual Meeting

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC

June 2nd 2025, 3:20pm

ASCO Annual Meeting

Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.

Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC

June 2nd 2025, 2:29pm

ASCO Annual Meeting

Adding induction toripalimab to chemotherapy followed by definitive chemoradiotherapy and consolidation therapy reduced risk for disease progression by 74%.

Rusfertide Shines as New Treatment Option in Polycythemia Vera

June 2nd 2025, 1:50pm

ASCO Annual Meeting

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics

June 2nd 2025, 12:55am

ASCO Annual Meeting

Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Dr Kuykendall on Clinical Benefit With Rusfertide in Phlebotomy-Dependent Polycythemia Vera

June 2nd 2025, 12:32am

ASCO Annual Meeting

Andrew Kuykendall, MD, discusses responses with rusfertide for patients with phlebotomy-dependent polycythemia vera.

Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC

June 1st 2025, 11:50pm

ASCO Annual Meeting

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer

June 1st 2025, 11:40pm

ASCO Annual Meeting

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Talquetamab Is Safe and Effective in R/R Multiple Myeloma

June 1st 2025, 10:49pm

ASCO Annual Meeting

Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.

Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC

June 1st 2025, 10:20pm

ASCO Annual Meeting

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

Mitomycin/BCG Combo Could Alleviate BCG Shortage Concerns for NMIBC

June 1st 2025, 9:16pm

ASCO Annual Meeting

BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.

Elraglusib Plus Chemotherapy Extends OS in Untreated Metastatic Pancreatic Ductal Adenocarcinoma

June 1st 2025, 8:50pm

ASCO Annual Meeting

Elraglusib plus gemcitabine/nab-paclitaxel displayed an OS benefit vs chemotherapy alone in untreated metastatic pancreatic ductal adenocarcinoma.

Sacituzumab Govitecan Plus Pembrolizumab Displays Activity in Early-Stage TNBC

June 1st 2025, 8:04pm

ASCO Annual Meeting

Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.

Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status

June 1st 2025, 8:03pm

ASCO Annual Meeting

Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.

Sacituzumab Tirumotecan Yields Superior Clinical Activity in EFGR+ NSCLC

June 1st 2025, 7:57pm

ASCO Annual Meeting

Sacituzumab tirumotecan showed statistically significant improvements in responses and survival vs docetaxel alone in advanced EGFR-mutant NSCLC.

x